Preliminary CommunicationsPROPRANOLOL—A MEDICAL TREATMENT FOR PORTAL HYPERTENSION?
References (7)
- et al.
Thermodilution cardiac output determination with a single flow-directed catheter
Am Heart J
(1972) - et al.
Direct transhepatic measurement of portal vein pressure using a thin needle. Comparison with wedged hepatic vein pressure
Gastroenterology
(1977) - et al.
Effect of pitressin on the splanchnic circulation in man
Circulation
(1961)
Cited by (269)
Management of Portal Hypertension
2022, Journal of Clinical and Experimental HepatologyAndrew K. Burroughs: a research hepatologist extraordinaire
2021, Annals of HepatologyNovel therapeutics for portal hypertension and fibrosis in chronic liver disease
2020, Pharmacology and TherapeuticsCitation Excerpt :NSBBs are the first class and the mainstay of drugs used to decrease PP, acting by blocking β1 adrenergic receptors to reduce heart rate and cardiac output, and inhibition of β2-induced splanchnic vasodilation, thereby reducing about 35% of portal venous inflow (Rodrigues et al., 2020). Since the first use of propranolol in preventing recurrent variceal bleeding (Lebrec, Nouel, Corbic, & Benhamou, 1980), several randomized controlled trials (RCTs) have shown the efficacy of NSBBs for preventing primary and secondary bleeding from esophagogastric varices (Garcia-Tsao & Bosch, 2010; Lebrec, Poynard, Hillon, & Benhamou, 1981; Pascal & Cales, 1987), and therefore NSBBs are considered first-line therapy in the primary and secondary prophylaxis of variceal hemorrhage (Angeli et al., 2018; Garcia-Tsao et al., 2017). Additionally, NSBBs have been shown to prevent other complications of portal hypertension, such as portal hypertensive gastropathy (Pérez-Ayuso et al., 1991), spontaneous bacterial peritonitis (Arab, Martin-Mateos, & Shah, 2018; Senzolo et al., 2009; Senzolo et al., 2009; Yu & Schwabe, 2017), ascites (Villanueva et al., 2019), and increase survival (Lo et al., 2008; Ngwa et al., 2020; Turco et al., 2020).
Beta-blockers in cirrhosis: Evidence-based indications and limitations
2020, JHEP ReportsCitation Excerpt :Almost 40 years ago, non-selective beta-blockers (NSBBs) emerged in the field of cirrhosis and portal hypertension (PH), as propranolol was shown to prevent recurrent variceal bleeding.1
Pharmacologic Management of Portal Hypertension
2019, Clinics in Liver Disease